GENinCode UK Ltd. (GB:GENI)
LSE:GENI
Top Page
GENinCode UK Ltd.
(LSE:GENI)
Select Model
Select Model
Rating:40Underperform
Price Target:
1.00 p
▼(-54.55% Downside)
Action:ReiteratedDate:02/04/26
The score is primarily weighed down by weak financial performance (persistent losses, negative operating cash flow, and declining equity). Technicals reinforce the risk with a clear downtrend and negative MACD, while valuation provides limited support due to a negative P/E and no dividend data.
Positive Factors
Revenue Growth Trend
The company has delivered a steady increase in revenue (2020–2024) and shows improving gross margin and free cash flow trends. Sustained top-line growth plus margin improvement supports a multi-month path to narrowing losses and eventual operating leverage if commercial traction continues.
Negative Factors
Persistent Net Losses
Recurring net losses and negative operating margins mean the business has not yet reached sustainable profitability. Persistent losses erode shareholder equity, increase dependence on external funding, and raise execution risk until the company secures consistent positive operating income.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trend
The company has delivered a steady increase in revenue (2020–2024) and shows improving gross margin and free cash flow trends. Sustained top-line growth plus margin improvement supports a multi-month path to narrowing losses and eventual operating leverage if commercial traction continues.
Read all positive factors
GENinCode UK Ltd. (GENI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£8.28M
Dividend YieldN/A
Average Volume (3M)1.99M
Price to Earnings (P/E)―
Beta (1Y)-0.63
Revenue Growth12.12%
EPS Growth54.24%
CountryUK
Employees42
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding753,041,140
10 Day Avg. Volume166,671
30 Day Avg. Volume1,986,185
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.90
Price to Sales (P/S)2.46
P/FCF Ratio-1.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)£34.86M
GENinCode UK Ltd. Business Overview & Revenue Model
Company Description
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provide...
How the Company Makes Money
GENinCode UK Ltd. generates revenue through multiple streams, primarily by providing genetic testing services to healthcare providers and patients. The company charges fees for its testing services, which can vary depending on the complexity and s...
GENinCode UK Ltd. Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
45
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.91M | 2.70M | 2.16M | 1.43M | 1.15M | 960.80K |
| Gross Profit | 1.37M | 1.43M | 1.02M | 632.00K | 593.00K | 523.02K |
| EBITDA | -4.78M | -4.69M | -6.65M | -5.57M | -4.10M | -1.03M |
| Net Income | -4.97M | -4.43M | -7.02M | -5.56M | -4.14M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 4.22M | 2.66M | 4.19M | 11.80M | 15.21M | 2.42M |
| Cash, Cash Equivalents and Short-Term Investments | 2.50M | 1.17M | 2.53M | 9.75M | 14.56M | 2.00M |
| Total Debt | 191.00K | 234.00K | 299.00K | 354.00K | 0.00 | 0.00 |
| Total Liabilities | 1.56M | 1.54M | 2.90M | 3.90M | 1.49M | 563.50K |
| Stockholders Equity | 2.66M | 1.13M | 1.29M | 7.90M | 13.72M | 1.86M |
Cash Flow | ||||||
| Free Cash Flow | -4.99M | -5.22M | -7.54M | -4.61M | -3.17M | -1.11M |
| Operating Cash Flow | -4.95M | -5.17M | -7.51M | -3.76M | -3.02M | -1.04M |
| Investing Cash Flow | -23.00K | 50.00K | 136.00K | -849.00K | -145.00K | -68.27K |
| Financing Cash Flow | 3.63M | 3.65M | -94.00K | -47.00K | 15.86M | 3.03M |
GENinCode UK Ltd. Technical Analysis
Positive
2.20
Price Trends
1.12
Negative
1.71
Negative
2.09
Negative
Market Momentum
-0.03
Negative
48.17
Neutral
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Positive. The current price of 2.2 is above the 20-day moving average (MA) of 1.09, above the 50-day MA of 1.12, and above the 200-day MA of 2.09, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.17 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:GENI.
GENinCode UK Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £10.23M | -1.31 | -104.73% | ― | 29.64% | 28.51% | |
47 Neutral | £15.25M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
45 Neutral | £20.09M | -2.69 | -58.27% | ― | 37.39% | -126.19% | |
40 Underperform | £8.28M | -0.47 | -181.41% | ― | 12.12% | 54.24% | |
40 Underperform | £8.58M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
39 Underperform | £8.52M | ― | 425.97% | ― | -4.48% | 61.09% |
* Healthcare Sector Average
GB:GENI
GENinCode UK Ltd.
1.10
-1.25
-53.19%
GB:CLBX
ANGLE plc
0.90
-6.85
-88.39%
GB:GDR
Genedrive
0.95
-0.54
-36.11%
GB:OBD
Oxford BioDynamics
0.20
-0.22
-52.38%
GB:RENX
Renalytix
1.95
-5.55
-74.00%
GB:ABDX
Abingdon Health PLC
8.00
2.00
33.33%
GENinCode UK Ltd. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
GENinCode Raises £4.1m Following Completion of WRAP Retail Offer
Positive
Jan 26, 2026
GENinCode Plc has completed its WRAP Retail Offer, launched on 21 January 2026, raising approximately £0.2 million through the issue of 20,014,095 new ordinary shares at 1 pence per share. Subject to shareholder approval of the relevant resol...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
GENinCode Raises £3.9m via Discounted Placing and Director-Backed Subscription
Neutral
Jan 22, 2026
GENinCode plc has conditionally raised £3.9 million before expenses through a heavily discounted placing and subscription of 388,145,000 new ordinary shares at 1p each, a 47.4% discount to the prior closing price. The fundraising, which inclu...
Private Placements and Financing
GENinCode Opens WRAP Retail Offer Alongside £3.5m Placing at Deep Discount
Neutral
Jan 21, 2026
GENinCode Plc has launched a retail share offer via the Winterflood Retail Access Platform to raise up to £500,000 through the issue of up to 50 million new ordinary shares at 1 pence per share, matching the price of a concurrent placing and ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
GENinCode Launches Discounted £3.5m Fundraise to Back US and European Expansion
Neutral
Jan 21, 2026
GENinCode plc has announced a conditional equity fundraising of at least £3.5 million via a placing to institutional investors and a subscription by entities associated with major shareholder Nestor Oller and certain directors, all at an issu...
Business Operations and StrategyProduct-Related Announcements
GENinCode Partners with Sohin Genetics to Distribute Heart Disease Risk Test in Mexico
Positive
Dec 17, 2025
GENinCode has announced a collaboration with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® test, a polygenic risk score for predicting and preventing coronary heart disease. This partnership aims to expand GENinCode’s ...
Business Operations and StrategyProduct-Related Announcements
GENinCode Partners with Thermo Fisher for CARDIO inCode-Score® Expansion
Positive
Dec 4, 2025
GENinCode UK Ltd. has announced a collaboration with Thermo Fisher Scientific to sell, distribute, and manufacture its CARDIO inCode-Score® test, which predicts genetic risk for coronary heart disease. This partnership aims to expand the test...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GENinCode’s CARDIO inCode-Score® Test Gains New York State Approval
Positive
Dec 3, 2025
GENinCode UK Ltd. has announced the approval of its CARDIO inCode-Score® test by the New York State Department of Health, enabling full state coverage under the US Centers for Medicare and Medicaid Services. This approval allows the company t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.